Opinion

Predicting Age Using Neuroimaging: Innovative Brain Ageing Biomarkers

James H. Cole\textsuperscript{1,*} and Katja Franke\textsuperscript{2,*}

The brain changes as we age and these changes are associated with functional deterioration and neurodegenerative disease. It is vital that we better understand individual differences in the brain ageing process; hence, techniques for making individualised predictions of brain ageing have been developed. We present evidence supporting the use of neuroimaging-based ‘brain age’ as a biomarker of an individual’s brain health. Increasingly, research is showing how brain disease or poor physical health negatively impacts brain age. Importantly, recent evidence shows that having an ‘older’-appearing brain relates to advanced physiological and cognitive ageing and the risk of mortality. We discuss controversies surrounding brain age and highlight emerging trends such as the use of multimodality neuroimaging and the employment of ‘deep learning’ methods.

Brain Scans Can Be Used to Predict Age

As the global population ages, the burden of age-associated functional decline and disease is increasing \cite{1}. Methods are required to predict who is at higher risk of age-associated deterioration, how this decline will progress, and which treatments are most appropriate. The ageing process is biologically complex \cite{2}, and despite the generally negative effects of ageing there is pronounced variation among people in the timing of manifestation of ageing effects (Figure 1). This variation in brain aging may contribute to the enormous variation in human lifespan and in the varying ages at which people develop age-related diseases. Potentially, a person’s underlying biological age (see Glossary) may differ from his or her chronological age and could be a better indicator of future risk of experiencing age-associated health issues.

Ageing results in marked changes to the structure and function of the brain. Cognitive decline and an increased risk of neurodegenerative diseases are a key source of the burden caused by ageing. However, pronounced individual differences are also seen in measures of the brain as people age \cite{3}. While the average age-driven trajectories of brain volume, cortical thickness, and white matter microstructure have been characterised in healthy people \cite{4–6}, a single person may differ considerably from the average. Potentially, the extent to which someone deviates from healthy brain-ageing trajectories could indicate underlying problems in outwardly healthy people and relate to the risk of cognitive ageing or age-associated brain disease. Hence, reliable biomarkers of brain ageing could be of great neuroscientific and clinical value.

Using structural or functional neuroimaging data, it is now possible to predict age \cite{7,8}. The most effective approaches to age prediction have used data from MRI scans of the brain and run a type of statistical analysis on the images called machine learning. By ‘learning’ the

Trends

Brain age can be predicted in individuals based on neuroimaging data using machine learning approaches to model trajectories of healthy brain ageing.

The predicted brain age for a new individual can differ from his or her chronological age; this difference appears to reflect advanced or delayed brain ageing.

Brain age has been shown to relate to cognitive ageing and multiple aspects of physiological ageing and to predict the risk of neurodegenerative diseases and mortality in older adults.

Various diseases, including HIV, schizophrenia, and diabetes, have been shown to make the brain appear older. Further, brain age is being used to identify possible protective or deleterious factors for brain health as people age.

Brain age is being actively developed to combine multiple measures of brain structure and function, capturing increasing amounts of detail on the ageing brain.

\textsuperscript{1}Computational, Cognitive & Clinical Neuroimaging Laboratory, Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK

\textsuperscript{2}Structural Brain Mapping Group, University Hospital Jena, Jena, Germany

*Correspondence: james.cole@imperial.ac.uk (J.H. Cole) and katja.franke@uni-jena.de (K. Franke).
Figure 1. Trajectories of Biological Ageing. As chronological age increases, there is a trend towards a higher risk of diseases and the onset of cognitive decline. This trend is thought to have a biological basis relating to the cumulative damage to cells and tissues acquired over time. While people who are generally healthy (grey arrow) reach the threshold for symptoms to appear at approximately similar ages, other people may follow different trajectories of biological ageing. This could be due to genetic differences or exposure to environmental effects that subtly increase the rate at which age-associated damage accumulates (blue arrow). Potentially, people may experience pronounced environmental influences, such as a brain injury or cerebral infection, leading to a marked acceleration of the rate of biological ageing (red line). In the current context, brain age may represent a measure of the underlying biological age of the brain. By measuring how far an individual is from the healthy brain ageing trajectory, researchers hope to be able to quantitatively advance and decelerate brain ageing and use this to predict individuals’ future trajectories and subsequent risk of age-associated health deterioration.

The relationship between patterns of data from brain scans and chronological age in a training dataset of healthy people, age predictions can be made using brain images from people not included in the initial training. The most accurate measures in adults have reported a mean absolute error (MAE) of <5 years [8–12], which can be measured with high test–retest reliability [9,13]. Moreover, in studies covering age ranges between early childhood and young adulthood the most accurate predictions result in MAEs of approximately only 1 year [14–16].

While using neuroimaging to predict age may be seen as an interesting academic exercise, it is also an important proof of concept, showing that the information extracted from a single MRI scan relates strongly to chronological age and that it can be used to make accurate age estimations from new scans. Furthermore, a growing body of research is demonstrating that so-called brain age has both clinical and broader scientific relevance. This paradigm has provided a new way to explore how the brain changes during ageing and how brain diseases interact with ‘normal’ brain ageing. Potentially, brain age could be used as a personalised biomarker of brain health during ageing, and this individual-specific nature is particularly important. The extensive study of group-mean differences in case-control studies of brain diseases has yielded few clinical applications. Conversely, brain age locates an individual within a normative ageing distribution. If this location can be shown to be relevant for health outcomes, brain age presents a framework for the application of neuroimaging clinically to characterise brain health. Here we outline the methods for predicting brain age, evaluate evidence for its use as an ageing biomarker, and discuss trends in the ongoing development of the paradigm.

Glossary

Ageing biomarker: a biological measurement that gives an estimate of an organism’s biological age based on the biological age of an organ, tissue, or cell.

Biological age: the hypothetical underlying age of an organism, defined by measuring some aspect of the organism’s biology. Biological age may differ from the organism’s chronological age and be a better indicator of residual lifespan, functional capacity, and risk of age-associated changes.

Brain age (or brain-predicted age): the predicted age of an individual derived using high-dimensional neuroimaging data in a machine learning framework. Brain age potentially represents a biomarker of the underlying ‘age’ of the brain, whereby an ‘older’ brain in adults indicates increased risks of neurodegenerative diseases and mortality.

Brain ageing: changes to the human brain that generally accompany ageing. These changes occur at molecular, cellular, and tissue levels and have characteristic functional and behavioural consequences (Box 1).

Deep learning: an extension of machine learning based on artificial neural networks. ‘Deep’ refers to the multiple layers of neural networks used, including one or more hidden layers. Each layer is used to transform input data into a different format that encodes something salient about the features contained in the data.

Features: a variable used in a machine learning algorithm or an aspect of a dataset that is of some relevance. In the context of brain age, features are local measures of brain structure or function (e.g., grey matter volume).

Gerontology: the scientific study of the aged and the ageing process.

Machine learning: a statistical approach derived from the study of artificial intelligence based on the concept that statistical models should be able to make accurate predictions from new ‘unseen’ data (either categorical, e.g., group membership, or continuous, e.g., age, IQ).

Magnetic resonance imaging (MRI): a medical imaging technique that capitalises on the inherent
How Does Neuroimaging-Based Brain Age Prediction Work?
The accuracy of brain age prediction relies on the fact that the brain changes as we age (Box 1) and that these changes are reasonably consistent between different people. Neuroimaging provides a unique window into the brain ageing process, allowing precise and reliable measurement of many aspects of brain structure and function. Recent advances in computing and the increasing availability of large neuroimaging datasets mean that researchers are now able to apply machine learning to the problem of age prediction (Figure 2, Key Figure and Box 2).

How Does Brain Age Relate to Other Ageing Measures?
The brain can be affected by peripheral physiological changes and having a healthy brain is essential for overall health. Therefore, measuring brain age could provide a window on general biological ageing as a potential ageing biomarker. To that end it is useful to consider whether brain age relates to other known facets of ageing. Measures of ageing typically used in gerontology include physiological, cognitive, and biological components. Physiological measurements of hand-grip strength, lung function, and walking speed are used to characterise general physical health as well as to predict risk of mortality in older adults [17–19]. Evidently, by using robust measurement techniques as proxies for underlying physiological variability, information about general health and residual lifespan can be obtained. Brain age appears to meet these criteria, as a recent large-scale study in 73-year-olds found a significant relationship between brain age and mortality risk, ascertained up to 7 years after scanning [20]. For every year that an individual’s brain was predicted to be older than their chronological age, there was a 6% increased risk of death. This study also showed that lower grip strength, lower forced expiratory volume, and slower walking time were all significantly associated with brain age, as was a composite measure of fluid cognition. This supports the idea that the brain is sensitive to general declines in health and suggests that brain age could be used as an ageing biomarker to make individualised predictions about mortality risk in older adults. The abovementioned study also compared brain age with other putative ageing biomarkers. Brain age did not correlate with either leukocyte telomere length or DNA-methylation age. Interestingly, brain age was a stronger predictor of mortality than the other measures, although a combined model of brain age with DNA-methylation age was the best predictor, illustrating the benefits of combining distinct ageing biomarkers.

Brain Diseases and Brain Age
If brain age can provide information about future health outcomes in the general population, this motivates research into potential causes of deviations from healthy brain ageing. Thus, physical properties of biological tissues when inside powerful magnetic fields. Particularly, hydrogen atoms contained in water within biological tissue behave in characteristic ways when the magnetic fields are manipulated and release energy in the form of radiofrequency (RF) pulses that can be recorded. These RF pulses can be transformed into 3D images that give information on brain volume, blood flow, brain function, and white matter microstructure, to name but a few biological characteristics. Voxel: a volume element, the 3D equivalent of a pixel. Voxels are the unit of resolution for MRI scans of the brain. Weight maps: voxel-wise maps of the brain where each voxel contains a numeric representation of the statistical model learned by a machine learning algorithm.
considering how specific diseases relate to brain age may help to isolate deleterious influences on brain health in later life. Understanding how variability in brain age within diverse clinical samples relates to other facets of non-communicable and age-related diseases could help to identify individuals at risk of poor health outcomes as ageing and disease processes interact. Potentially, diseases result in increases of brain ageing as a one-off "hit" or a progressive acceleration of the process. Alternatively, the presence of a disease may not cause brain ageing per se but occurs on top of underlying individual differences in normal brain ageing. This could mean that the effects of that disease are exacerbated in those with ‘older’- as opposed to ‘younger’-appearing brains. Either way, measuring brain age in disease groups could be fruitful in quantifying some of the heterogeneity within a disease, improving the identification of individuals at higher risk of poor health outcomes. Consequently, brain age could be used as general marker of poorer brain health to help stratify the enrolment of individuals into clinical trials of therapies aimed at improving brain health in older adults who may not have observable clinical or cognitive impairments.
While aetiologically and pathophysiological distinct, many diseases seem to have common, secondary effects on the brain. For example, brain injury, multiple sclerosis, major depressive disorder, and Alzheimer’s disease are all associated with a heightened immune response, neuroinflammation, oxidative stress, mitochondrial dysfunction, and epigenetic alterations [21–30]. Notably, all of these phenomena are also implicated in the biology of ‘normal’ ageing [2]. Furthermore, a number of diseases have been proposed to exacerbate biological ageing, including Down’s syndrome, HIV and traumatic brain injury [31–33]. Given the relationship between ageing and disease risk, it is unsurprising that common underlying mechanisms may be present. However, the availability of ageing biomarkers now allows researchers to evaluate evidence of abnormal ageing in specific diseases, and in the context of brain diseases brain age is likely to be a particularly relevant measure. It is hoped that combining ageing-related biomarkers with more disease-specific biomarkers will lead to further improvements in diagnostic and prognostic modelling, moving closer to clinical applications of neuroimaging.

A growing number of neuropsychiatric diseases have been associated with increases in brain age (Table 1). These include traumatic brain injury [34], schizophrenia [12,35,36], epilepsy [37], Down’s syndrome [38], HIV infection [39], mild cognitive impairment, and Alzheimer’s disease [13,40–42]. Similar results have also been seen in peripheral conditions and non-communicable diseases, such as mid-life obesity [43] and diabetes [44], suggesting again that the brain is also sensitive to deteriorations in general physical health. These outwardly disparate conditions may share some common pathological neurobiological components – effects secondary to the disparate primary pathological processes – that result in an increase in age-associated loss of brain volume. Interestingly, brain age was more sensitive in showing differences between groups than total and regional brain volumes [40]. Methodologically, the variance in brain age is largely explained by a composite of brain volume, age, and sex, although it also contains unique variance not captured by commonly used measures. Thus, analysing brain age in these contexts provides a novel way to capture individual differences within the general population as well as disease groups that relate to additional facets of various diseases or even predict future outcomes. For example, increased brain age in people with mild cognitive impairment has been associated with greater risk of developing Alzheimer’s disease within 3 years [40,42].
Despite the many different causes of neuropathology, the response mechanisms of the brain seem to be relatively limited, whether the cause is infectious, traumatic, or genetic. Hence, the brain age studies can be seen as evidence that common secondary mechanisms, observed across diseases, may relate to those seen in healthy ageing and may be important for some of the neurological, cognitive, and behavioural consequences of brain diseases. In line with this, cognitive performance has also been assessed in studies of brain age. In general, there are significant relationships between global cognitive performance and brain age, these being more pronounced in disease samples [10,13,15,20,34,39,40,42]. This supports the idea that brain ageing and cognitive ageing are linked, although the modest strength of these associations

Table 1. Studies Assessing Brain Age in Neurological and Psychiatric Diseases

<table>
<thead>
<tr>
<th>Clinical group</th>
<th>n</th>
<th>Age mean (SD)</th>
<th>Features for brain age</th>
<th>Mean brain age difference (years)</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s disease</td>
<td>102</td>
<td>76 (8)</td>
<td>GM</td>
<td>10.0</td>
<td>[8]</td>
</tr>
<tr>
<td>Alzheimer’s disease</td>
<td>150</td>
<td>75 (8)</td>
<td>GM</td>
<td>Baseline: 6.7 Follow up (2 years): 9.0</td>
<td>[13]</td>
</tr>
<tr>
<td>Alzheimer’s disease (APOE e4 carriers/ non-carriers)</td>
<td>101/49</td>
<td>74 (7)/76 (9)</td>
<td>GM</td>
<td>Baseline: 5.8/6.2 Follow up (2 years): 8.3/7.7</td>
<td>[42]</td>
</tr>
<tr>
<td>Alzheimer’s disease</td>
<td>411</td>
<td>75 (7)</td>
<td>Hippocampus</td>
<td>7</td>
<td>[61]</td>
</tr>
<tr>
<td>At risk mental state for psychosis</td>
<td>89</td>
<td>25 (6)</td>
<td>GM</td>
<td>1.7</td>
<td>[35]</td>
</tr>
<tr>
<td>Bipolar disorder</td>
<td>22</td>
<td>38 (11)</td>
<td>GM</td>
<td>−1.3 (males: −1.9/females: −0.8)</td>
<td>[36]</td>
</tr>
<tr>
<td>Borderline personality disorder</td>
<td>57</td>
<td>26 (7)</td>
<td>GM</td>
<td>3.1</td>
<td>[35]</td>
</tr>
<tr>
<td>Diabetes mellitus type 2</td>
<td>98</td>
<td>65 (8)</td>
<td>GM</td>
<td>4.6</td>
<td>[44]</td>
</tr>
<tr>
<td>Diabetes mellitus type 2</td>
<td>12</td>
<td>63 (7)</td>
<td>GM</td>
<td>Baseline: 5.1 Follow up (4 years): 5.9</td>
<td>[44]</td>
</tr>
<tr>
<td>Down’s syndrome</td>
<td>46</td>
<td>42 (9)</td>
<td>Whole brain</td>
<td>2.5</td>
<td>[38]</td>
</tr>
<tr>
<td>Epilepsy (medically refractory/newly diagnosed)</td>
<td>94/42</td>
<td>32 (14)/31 (11)</td>
<td>Whole brain</td>
<td>4.5/0.9</td>
<td>[37]</td>
</tr>
<tr>
<td>HIV</td>
<td>162</td>
<td>56</td>
<td>Whole brain</td>
<td>2.2</td>
<td>[39]</td>
</tr>
<tr>
<td>Major depression</td>
<td>104</td>
<td>42 (8)</td>
<td>GM</td>
<td>4.0</td>
<td>[35]</td>
</tr>
<tr>
<td>Mild cognitive impairment, progressive</td>
<td>112</td>
<td>74 (7)</td>
<td>GM</td>
<td>Baseline: 6.2 Follow up (3 years): 9.0</td>
<td>[13]</td>
</tr>
<tr>
<td>Mild cognitive impairment, progressive (early/late)</td>
<td>58/75</td>
<td>74 (7)/75 (7)</td>
<td>GM</td>
<td>8.7/5.6</td>
<td>[40]</td>
</tr>
<tr>
<td>Mild cognitive impairment, progressive (APOE e4 carriers/non-carriers)</td>
<td>78/34</td>
<td>74 (6)/75 (9)</td>
<td>GM</td>
<td>Baseline: 5.8/5.5 Follow up (3 years): 8.7/7.3</td>
<td>[42]</td>
</tr>
<tr>
<td>Mild cognitive impairment, stable</td>
<td>36</td>
<td>77 (6)</td>
<td>GM</td>
<td>Baseline: −0.5 Follow up (3 years): −0.4</td>
<td>Franke, 2012 [13]</td>
</tr>
<tr>
<td>Mild cognitive impairment, stable (APOE e4 carriers/non-carriers)</td>
<td>14/22</td>
<td>77 (6)/77 (6)</td>
<td>GM</td>
<td>−0.9/−0.9 Follow up (3 years): 0.0/−0.6</td>
<td>[42]</td>
</tr>
<tr>
<td>Obesity</td>
<td>227</td>
<td>58 (17)</td>
<td>WM</td>
<td>10</td>
<td>[43]</td>
</tr>
<tr>
<td>Objective cognitive impairment (mild/ major)</td>
<td>632/251</td>
<td>58 (15)/58 (16)</td>
<td>Whole brain (multimodal)</td>
<td>0.7/1.7</td>
<td>[10]</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>141</td>
<td>28 (12)</td>
<td>GM</td>
<td>5.5</td>
<td>[35]</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>341</td>
<td>34 (12)</td>
<td>GM</td>
<td>Baseline: 3.4 Follow up (4 years): 4.3</td>
<td>[12]</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>45</td>
<td>34 (10)</td>
<td>GM</td>
<td>2.6 (males: 3.4/females: 1.1)</td>
<td>[36]</td>
</tr>
<tr>
<td>Traumatic brain injury</td>
<td>99</td>
<td>38 (12)</td>
<td>GM/WM</td>
<td>4.7/6.0</td>
<td>[34]</td>
</tr>
</tbody>
</table>

Features for brain age are reported as the aspects of brain structure used as predictors in the brain-age model. GM, grey matter; WM, white matter. Data formats include voxel-wise 3D images and summary measures of cortical thickness and subcortical volumes. Multimodal refers to a combination of structural and functional MRI.
suggests that further method development is needed to better capture the variation in brain structure and cognitive performance.

**Improving Individual Brain Health**

While there may be many deleterious influences on brain age, there is also evidence of protective factors. Significant associations with decreased brain age and markers of good health in cognitively healthy elderly [45] and the general population [46] have been reported. Furthermore, the number of years of education and a self-reported measure of physical activity (number of stairs climbed daily) were reported to be significantly associated with a lower brain age in individuals aged 19–79 years [47]. Alongside this, recent studies have observed a reduction in brain age in long-term practitioners of meditation [48] and in amateur musicians [49].

Although only cross-sectional, such results are promising. They suggest that interventions could be effective in slowing or potentially even reversing brain ageing, reducing the risk of future cognitive decline and age-associated disease. However, prospective longitudinal studies of positive influences on brain age remain to be conducted. This represents the next, and crucial, step in developing a framework for the evaluation of potential treatments for age-associated brain deterioration.

**Controversies around Brain Age**

While the brain age paradigm offers a powerful approach to the investigation of brain ageing, it has attracted some criticisms, either technical or philosophical. For instance, some consider the only factor that affects age to be time; thus, ageing per se cannot deviate from its chronological course. This criticism applies to all potential ageing biomarkers, instead suggesting that there is limited biological variability in ageing and that deviations are due to specific pathological processes, not reflecting an extension of normal ageing. However, there is strong support for the hypothesis that ageing results from cumulative biological damage [50]. It follows from this that variable exposure to the causes of this cumulative damage would result in individual differences in rates of underlying biological damage. Furthermore, the fact that ageing is the major risk for numerous diseases strongly suggests that biological ageing and disease are intrinsically linked. Beyond this, we argue that whether or not an increased brain age indicates that a brain is actually ‘older’ is not the chief consideration. If brain age (or other biologically predicted ages, for that matter) can be a useful neuroscientific and clinical tool, it warrants further exploration.

Another criticism of brain age is that by condensing whole-brain voxel-wise information into a single number, it is overly ‘black box’. By not scrutinising exactly which features of a brain scan are used to predict age, important neuroscientific information may be disregarded and it is unclear precisely what information age prediction is based on. However, there are several important reasons why interpreting the ‘weight maps’ derived from machine learning is complicated and does not offer a straightforward interpretation in the context of brain ageing [51]. First, no one part of the brain is the sole driver of ageing; brain ageing is a global phenomenon. Second, age-related changes to the brain are subtle, nonlinear, and spatially distributed and vary between individuals [4,6,52]. The advantage of the brain age paradigm is that, by using machine learning, the model can learn a range of different brain structures that may be healthy. This avoids reductively focusing on the average, which is likely to be unrepresentative of any single individual.

A final criticism of brain age is that it relies on using the resulting error in prediction (i.e., the difference between the predicted age and the chronological age) as a metric for further analysis. Statistically, this is equivalent to using the residuals for an individual from a linear regression.
model. Basing clinical or neuroscientific interpretations on error may be semantically dubious, as in theory more accurate models would reduce this error. Crucially, however, the key to determining the validity of brain age lies in external validation with other characteristics measured in the same individuals. For example, the fact that the error metric (e.g., brain-predicted age difference) relates to cognitive performance, ageing fitness and, subsequent survival [13,15,20,40,42,47] strongly supports the idea that, by quantifying this error, clinically and biologically meaningful insights can be derived.

Concluding Remarks

The emerging field of brain age prediction is evolving rapidly and an increasing number of researchers are employing brain age analysis to explore brain ageing in health and disease. A number of promising trends are developing. These include the combination of multiple neuroimaging modalities; for example, combining structural and functional MRI data or multiple structural MRI modalities (T2*, diffusion MRI) resulting in improved prediction performance [10,53]. Combined predictors potentially better capture the various facets of brain ageing, including brain atrophy, iron deposition, and alterations of white matter microstructure (see Outstanding Questions).

Another development is the increasing availability of large datasets. Key to accurate machine learning is having a sufficient number of examples to learn from. Initiatives such as the International Neuroimaging Data-Sharing Initiative (INDI) (http://fcon_1000.projects.nitrc.org/) and NeuGrid4U (https://neugrid4you.eu/) encourage the sharing of existing datasets. Groundbreaking projects like the Human Connectome Project and UK Biobank have been explicitly designed to share data and are making unprecedented amounts of neuroimaging data accessible.

Important for leveraging these larger and more complex datasets is innovation in computational statistics, to optimise algorithms for the prediction of brain age [54]. In particular, deep learning methods show considerable promise [9]. The ‘hidden’ layers in deep learning allow data-driven representation of various global and local data features, meaning that hitherto unknown relationships can be more accurately identified. One benefit of deep learning particular to neuroimaging is the removal the reliance on data pre-processing to extract meaningful features. Such features can be automatically encoded by deep neural networks, avoiding the model-dependent decisions used in image pre-processing (e.g., registration algorithm, template selection). While the computational demands for deep learning are high, the added benefits are likely to outweigh the costs, and deep learning might enjoy increasing interest in brain age analysis as in other neuroimaging research.

The ability to predict a person’s brain age using neuroimaging data is increasingly providing insights into both positive and negative effects on age-associated brain changes and is shedding new light on how diseases affect the ageing brain. Furthermore, brain age has the potential to identify individuals at risk of experiencing advanced biological ageing and thus could provide a biomarker of age-associated health problems. As the technical aspects of brain age analysis are further developed, the possibility that neuroimaging-based measures of brain age could be used to evaluate neuroprotective interventions and therapeutics comes closer to being realised.

Acknowledgments

The authors thank Drs Rob Leech, Romy Lorenz, and Ines Violante for their insightful and instructive comments on drafts of this Opinion article. This work was supported by the German Research Foundation (DFG) (Project FR 3709/1-1 to K.F.). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Outstanding Questions

Does the brain age uniformly across different cell populations and tissue types? Or do different parts of the brain age at different rates? If so, how does this vary across individuals? Will brain age prediction models including multi-modalities capture these variations more accurately?

To what extent do participant motion and type of MRI scanner influence predictions of brain age? This is increasingly important with larger datasets pooling data from multiple sources.

How much more informative is structural brain age compared with MRI-derived measures of total or regional brain volume? While it is clear that the high-dimensional nature of brain age allows substantially more accurate predictions of age and thus qualifies more as an ageing biomarker, the added value for prediction of outcomes needs to be assessed on a case-by-case basis.

Can brain age be used as an outcome measure in a clinical trial of neuroprotective or antiaging interventions? A link between increased brain age, cognitive decline, and mortality has already been demonstrated, as has the test–retest reliability of the measure. Nevertheless, further research is necessary to validate whether neuroimaging markers of brain ageing are amenable to intervention and have specific clinical relevance.

Can brain age be used to predict the onset and individual trajectory of progression in specific neurodegenerative diseases? Brain age has been shown to be sensitive in indicating subtle and widespread changes of individual brain structure in a variety of clinical and population-based samples. However, further development of the method and research in various disease samples are required to enable the use of brain age for disease-specific predictions.
References


36. Nenadic, I. et al. (2017) BrainAGE score indicates accelerated brain aging in schizophrenia, but not bipolar disorder. Psychiatry Res. 266, 86–89


